Two Systems That Must Work Together

In cancer research, we often study systems separately. We look at tumor genetics, or we focus on the immune system, or we analyze epigenetic regulation. Each of these areas has produced important discoveries. But in recent years, it has become clear to me that some of the most meaningful progress happens when we study how these systems interact.

One of the most exciting areas today is the connection between epigenetics and the immune system. This relationship, which we call the epigenetic-immune axis, helps explain why some cancers respond to immunotherapy while others do not. It also opens new possibilities for combining treatments in smarter ways.

Why Immunotherapy Does Not Work for Everyone

Immunotherapy has transformed cancer care for many patients. Drugs that activate the immune system, such as checkpoint inhibitors, have shown remarkable success in cancers like melanoma and lung cancer. These therapies help the immune system recognize and attack tumor cells.

However, in breast cancer and several other cancers, the response to immunotherapy has been more limited. Some tumors are described as “cold,” meaning they do not attract or activate immune cells effectively. Others actively suppress immune activity, creating a protective environment that allows cancer cells to survive.

This raises an important question: why does the immune system fail to recognize some tumors?

The answer is not only genetic. It is also epigenetic.

How Epigenetics Controls Immune Visibility

Epigenetic mechanisms control which genes are turned on or off in a cell. This includes genes involved in immune recognition. For example, cancer cells may silence genes that produce proteins needed for immune detection, such as antigen presentation molecules.

If these genes are turned off, the immune system has a harder time identifying cancer cells as abnormal. The tumor becomes less visible, even if it carries many mutations.

In my own research on breast cancer, I have studied how epigenetic regulators influence gene expression programs that define cell identity. These same regulatory systems can also affect how cancer cells interact with the immune system. When key genes are silenced through DNA methylation or chromatin changes, the tumor may escape immune surveillance.

This is one reason why immunotherapy alone may not be enough. The immune system cannot attack what it cannot see.

Reversing Silence to Restore Recognition

One promising strategy is to use epigenetic therapies to reverse this silencing. Drugs that target DNA methylation or histone modifications can reactivate genes that were previously turned off.

When this happens, cancer cells may begin to express proteins that signal their presence to the immune system. They may also produce molecules that attract immune cells into the tumor environment.

This process can effectively turn a “cold” tumor into a “hot” one. Once the tumor becomes visible, immunotherapy has a better chance of working.

In this way, epigenetic therapy does not replace immunotherapy. It prepares the tumor for immune attack.

Combining Therapies for Greater Impact

The idea of combining epigenetic therapy with immunotherapy is gaining strong interest. Each approach addresses a different part of the problem.

• Epigenetic therapy helps restore gene expression and immune visibility
• Immunotherapy helps activate and sustain the immune response

Together, they may produce a stronger and more durable effect.

For example, a patient might receive a DNA methylation inhibitor to reactivate silenced immune-related genes. This could be followed by a checkpoint inhibitor that enables T cells to attack the tumor more effectively. Early studies suggest that this combination can improve response rates in certain cancers.

The timing and sequence of these treatments are also important. We must understand when to introduce each therapy to achieve the best outcome. This is an area where more research is needed.

Overcoming Resistance Through Integration

Resistance remains one of the biggest challenges in cancer treatment. Tumors often adapt to therapy, whether it is chemotherapy, hormone therapy, or immunotherapy.

Epigenetic changes are a key driver of this adaptation. They allow cancer cells to quickly adjust gene expression in response to stress. This flexibility helps tumors survive.

By targeting epigenetic mechanisms, we may be able to limit this adaptability. At the same time, activating the immune system creates additional pressure on the tumor.

The combination of these approaches may reduce the likelihood that cancer cells can escape. Instead of giving the tumor multiple opportunities to adapt, we create a more coordinated and sustained attack.

The Role of the Tumor Microenvironment

The epigenetic-immune axis also extends beyond cancer cells themselves. The tumor microenvironment plays an important role in shaping immune activity.

Fibroblasts, immune cells, and extracellular signals can all influence how epigenetic changes affect the tumor. Some signals may promote immune suppression, while others may support immune activation.

Understanding these interactions is essential for designing effective combination therapies. It is not enough to target the cancer cell alone. We must consider the entire system in which it exists.

Moving Toward Personalized Strategies

Not all patients will respond to the same combination of therapies. This is why personalization is so important.

By analyzing epigenetic patterns and immune profiles, we can begin to identify which patients are most likely to benefit from combined approaches. Some tumors may have strong epigenetic silencing of immune genes. Others may already have active immune environments but need additional support.

In the future, I believe we will use integrated biomarkers to guide treatment decisions. These markers will reflect both epigenetic status and immune activity, allowing us to design therapies that are tailored to each patient.

Teaching the Next Generation to Think Across Systems

As a mentor, I encourage my students to think beyond single pathways. The epigenetic-immune axis is a clear example of why this is necessary. Cancer is not controlled by one mechanism. It is shaped by multiple systems that interact with each other.

Students must learn to connect these systems. They must understand how changes in gene regulation affect immune behavior, how therapy influences both, and how the tumor adapts in response.

This kind of thinking prepares them to contribute to the next generation of cancer therapies.

A New Direction in Cancer Treatment

The intersection of epigenetics and immunology represents a powerful new direction in cancer research. By combining therapies that restore gene expression with those that activate the immune system, we can approach cancer from multiple angles at once.

This strategy is still developing, but it holds great promise. It reminds us that cancer is not just a genetic disease. It is a disease of regulation, interaction, and adaptation.

By understanding and targeting these layers together, we move closer to treatments that are not only more effective, but also more durable.